Strategies for MMP inhibition in cancer: innovations for the post-trial era (original) (raw)

• Liotta, L. A. et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284, 67–68 (1980).
  CAS PubMed Google Scholar
• López-Otín, C. & Overall, C. M. Protease degradomics, a new challenge for proteomics. Nature Rev. Mol. Cell Biol. 3, 509–519 (2002).Introduction of novel concepts and proteomic approaches for protease profiling in pathological conditions, including cancer.
  Google Scholar
• Brinckerhoff, C. E. & Matrisian, L. M. Matrix metalloproteinases: a tail of a frog that became a prince. Nature Rev. Mol. Cell Biol. 3, 207–214 (2002).Comprehensive chronicle of the MMP history.
  CAS Google Scholar
• Bramhall, S. R. et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer 86, 1864–1870 (2002).First report of a placebo–controlled double-blind study of success in treating cancer with an MMPI.
  CAS PubMed PubMed Central Google Scholar
• Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387–2392 (2002).Excellent analysis of the current status of MMPIs for cancer treatment.
  CAS PubMed Google Scholar
• Egeblad, M. & Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2, 163–175 (2002).Excellent and exhaustive description of the newly identified functions of MMPs in cancer.
  Google Scholar
• McCullagh, K., Wadsworth, H. & Hann, M. Carboxyalkyl peptide derivatives. European Patent Application. EU 126,974, pp 1–111 (1984).
• Blobel, C. P. Functional and biochemical characterization of ADAMs and their predicted role in protein ectodomain shedding. Inflamm. Res. 51, 83–84 (2002).
  CAS PubMed Google Scholar
• Cal, S. et al. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene 283, 49–62 (2002)
  CAS PubMed Google Scholar
• Amour, A. et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 473, 275–279 (2000).
  CAS PubMed Google Scholar
• Kashiwagi, M., Tortorella, M., Nagase, H. & Brew, K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem. 276, 12501–12504 (2001).
  CAS PubMed Google Scholar
• Naglich, J. G. et al. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res. 61, 8480–8485 (2001).
  CAS PubMed Google Scholar
• Bissell, M. J. & Radisky, D. Putting tumours in context. Nature Rev. Cancer 1, 46–54 (2001).
  CAS Google Scholar
• Overall, C. M. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules and exosites. Mol. Biotechnol. 22, 51–86 (2002).
  CAS PubMed Google Scholar
• Uría, J. A. & López-Otín, C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res. 60, 4745–4751 (2000).
  PubMed Google Scholar
• Seiki, M. Membrane-type matrix metalloproteinases. APMIS 107, 137–143 (1999).
  CAS PubMed Google Scholar
• Morgunova, E. et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 284, 1667–1670 (1999).
  CAS PubMed Google Scholar
• Steiner, D. F. The proprotein convertases. Curr. Opin. Chem. Biol. 2, 31–39 (1998).
  CAS PubMed Google Scholar
• Gururajan, R., Grenet, J., Lahti, J. M. & Kidd, V. J. Isolation and characterization of two novel metalloproteinase genes linked to the Cdc2L locus on human chromosome 1p36. 3. Genomics 52, 101–106 (1998).
  CAS PubMed Google Scholar
• Velasco, G. et al. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J. Biol. Chem. 274, 4570–4576 (1999).
  CAS PubMed Google Scholar
• Sternlicht, M. D. et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 98, 137–146 (1999).
  CAS PubMed PubMed Central Google Scholar
• Noe, V. et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J. Cell Sci. 114, 111–118 (2001).
  CAS PubMed Google Scholar
• Fingleton, B., Vargo-Gogola, T., Crawford, H. C. & Matrisian, L. M. Matrilysin (MMP-7) expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 3, 459–468 (2001).
  CAS PubMed PubMed Central Google Scholar
• McQuibban, G. A. et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202–1206 (2000).A breakthrough in the use of the yeast two-hybrid system to screen for substrates of extracellular proteases, with the finding that chemokines are novel members of the MMP substrate degradome.
  CAS PubMed Google Scholar
• Cornelius, L. A. et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol. 161, 6845–6852 (1998).
  CAS PubMed Google Scholar
• Fini, M. E., Cook, J. R., Mohan, R. & Brinckerhoff, C. E. in Matrix Metalloproteinases (eds Parks, W. C. & Mecham, R. P.) 299–356 (Academic Press, New York, 1998).
  Google Scholar
• Westermarck, J. & Kähäri, V. M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13, 781–792 (1999).
  CAS PubMed Google Scholar
• Kheradmand, F., Werner, E., Tremble, P., Symons, M. & Werb, Z. Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change. Science 280, 898–902 (1998).
  CAS PubMed Google Scholar
• Overall, C. M., Wrana, J. L. & Sodek, J. Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-β. J. Biol. Chem. 264, 1860–1869 (1989).
  CAS PubMed Google Scholar
• Uría, J. A., Jiménez, M. G., Balbín, M., Freije, J. M. P. & López-Otín, C. Differential effects of transforming growth factor-β on the expression of collagenase-1 and collagenase-3 in human fibroblasts. J. Biol. Chem. 273, 9769–9777 (1998).
  PubMed Google Scholar
• Overall, C. M. Repression of tissue inhibitor of matrix metalloproteinase expression by all-_trans_-retinoic acid in rat bone cell populations: comparisons with transforming growth factor-β1. J. Cell. Physiol. 164, 17–25 (1995).
  CAS PubMed Google Scholar
• Jiménez, M. J. et al. A regulatory cascade involving retinoic acid, Cbfa1, and matrix metalloproteinases is coupled to the development of a process of perichondrial invasion and osteogenic differentiation during bone formation. J. Cell Biol. 155, 1333–1344 (2001).
  PubMed PubMed Central Google Scholar
• Simon, C., Goepfert, H. & Boyd, D. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res. 58, 1135–1139 (1998).
  CAS PubMed Google Scholar
• Johansson, N. et al. Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J. Cell Sci. 113, 227–235 (2000).
  CAS PubMed Google Scholar
• Pendás, A. M., Balbin, M., Llano, E., Jimenez, M. G. & López-Otín, C. Structural analysis and promoter characterization of the human collagenase-3 gene (MMP13). Genomics 40, 222–233 (1997).
  PubMed Google Scholar
• Bond, M., Baker, A. H. & Newby, A. C. Nuclear factor κB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem. Biophys. Res. Commun. 264, 561–567 (1999).
  CAS Google Scholar
• Han, Y. P., Tuan, T. L., Wu, H., Hughes, M. & Garner, W. L. TNF-α stimulates activation of pro-MMP2 in human skin through NF-κB mediated induction of MT1-MMP. J. Cell Sci. 114, 131–139 (2001).
  CAS PubMed Google Scholar
• Ala-aho, R. et al. Inhibition of collagenase-3 (MMP-13) expression in transformed human keratinocytes by interferon-γ is associated with activation of extracellular signal-regulated kinase-1,2 and STAT1. Oncogene. 19, 248–257 (2000).
  CAS PubMed Google Scholar
• Crawford, H. C. et al. The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol. Cell Biol. 21, 1370–1383 (2001).
  CAS PubMed PubMed Central Google Scholar
• Nakamoto, T. et al. CIZ, a zinc finger protein that interacts with p130(cas) and activates the expression of matrix metalloproteinases. Mol. Cell Biol. 20, 1649–1658 (2000).
  CAS PubMed PubMed Central Google Scholar
• Sun, Y. et al. p53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression. J. Biol. Chem. 274, 11535–11540 (1999).
  CAS PubMed Google Scholar
• Sun, Y. et al. Wild-type and mutant p53 differentially regulate the gene expression of human collagenase-3 (hMMP-13). J. Biol. Chem. 275, 11327–11332 (2000).
  CAS PubMed Google Scholar
• Kerr, L. D., Miller, D. B. & Matrisian, L. M. TGF-β1 inhibition of transin/stromelysin gene expression is mediated through a Fos binding sequence. Cell 61, 267–278 (1990).
  CAS PubMed Google Scholar
• Benderdour, M. et al. A novel negative regulatory element in the human collagenase-3 proximal promoter region. Biochem. Biophys. Res. Commun. 291, 1151–1159 (2002).
  CAS PubMed Google Scholar
• Rutter, J. L. et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 58, 5321–5325 (1998).
  CAS PubMed Google Scholar
• Biondi, M. L. et al. MMP1 and MMP3 polymorphisms in promoter regions and cancer. Clin. Chem. 46, 2023–2024 (2000).
  CAS PubMed Google Scholar
• Springman, E. B., Angleton, E. L., Birkedal-Hansen, H. & Van Wart, H. E. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a 'cysteine switch' mechanism for activation. Proc. Natl Acad. Sci. USA 87, 364–368 (1990).
  CAS PubMed PubMed Central Google Scholar
• Becker, J. W. et al. Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protein Sci. 4, 1966–1976 (1995).
  CAS PubMed PubMed Central Google Scholar
• Bannikov, G. A., Karelina, T. V., Collier, I. E., Marmer, B. L. & Goldberg, G. I. Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide. J. Biol. Chem. 277, 16022–16027 (2002).
  CAS PubMed Google Scholar
• Overall, C. M. et al. Domain interactions in the gelatinase A:TIMP-2:MT1-MMP activation complex: the ectodomain of the 44-kDa form of membrane type-1 matrix metalloproteinase does not modulate gelatinase A activation. J. Biol. Chem. 275, 39497–39505 (2000).
  CAS PubMed Google Scholar
• Holmbeck, K. et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99, 81–92 (1999).First presentation of a Mmp-knockout mouse that has a dramatic phenotype.
  CAS PubMed Google Scholar
• Knauper, V. et al. Cellular mechanisms for human collagenase-3 (MMP-13) activation: evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J. Biol. Chem. 271, 17124–17131 (1996).
  CAS PubMed Google Scholar
• Sato, H. et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370, 61–65 (1994).Identification of the first MT-MMP that is responsible for the cellular activation of MMP-2, and a potential furin-cleavage site in a MMP.
  CAS PubMed Google Scholar
• Morrison, C. J. et al. Cellular activation of MMP-2 (gelatinase A) by MT2-MMP occurs via a TIMP-2 independent pathway. J. Biol. Chem. 276, 47402–47410 (2001).Presentation of the first TIMP-2-independent cellular activation pathway of MMP-2 and the role of TIMP-4 in this process.
  CAS PubMed Google Scholar
• Steffensen, B., Bigg, H. F. & Overall, C. M. The involvement of the fibronectin type II-like modules of human gelatinase A in cell surface localization and activation. J. Biol. Chem. 273, 20622–20628 (1998).
  CAS PubMed Google Scholar
• Strongin, A. Y. et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 270, 5331–5338 (1995).A classical paper on the mechanistic aspects of MMP-2 activation by MT1-MMP and the formation of a trimolecular complex on the cell surface.
  CAS PubMed Google Scholar
• Zucker, S. et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J. Biol. Chem. 273, 1216–1222 (1998).
  CAS PubMed Google Scholar
• Overall, C. M. et al. Identification of the tissue inhibitor of metalloproteinases-2 (TIMP-2) binding site on the hemopexin carboxyl domain of human gelatinase A by site-directed mutagenesis. The hierarchical role in binding TIMP-2 of the unique cationic clusters of hemopexin modules III and IV. J. Biol. Chem. 274, 4421–4429 (1999).
  CAS PubMed Google Scholar
• Morgunova, E, Tuuttila, A., Bergmann, U. & Tryggvason, K. Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc. Natl Acad. Sci. USA 99, 7414–7419 (2002).
  CAS PubMed PubMed Central Google Scholar
• Deryugina, E. I. et al. MT1-MMP initiates activation of pro-MMP-2 and integrin αvβ3 promotes maturation of MMP-2 in breast carcinoma cells. Exp. Cell Res. 263, 209–223 (2001).
  CAS PubMed Google Scholar
• Pei, D. & Weiss, S. J. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 375, 244–247 (1995).Comprehensive protein-engineering study that elucidates the furin mechanism of MMP activation.
  CAS PubMed Google Scholar
• Pei, D., Kang, T. & Qi, H. Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J. Biol. Chem. 275, 33988–33997 (2000).
  CAS PubMed Google Scholar
• Velasco, G. et al. Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res. 60, 877–882 (2000).
  CAS PubMed Google Scholar
• Brew, K., Dinakarpandian, D. & Nagase, H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477, 267–283 (2000).
  CAS PubMed Google Scholar
• Khokha, R. et al. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 243, 947–950 (1989).One of the first papers ever reported on the use of antisense RNA to modulate a gene in vivo with a clear demonstration of the importance of the MMP/TIMP balance in maintaining a normal cell phenotype. Disruption of this balance is shown to cause cancer.
  CAS PubMed Google Scholar
• Jiang, Y., Goldberg, I. D. & Shi, Y. E. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21, 2245–2252 (2002).
  CAS PubMed Google Scholar
• Oh, J. et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107, 789–800 (2001).
  CAS PubMed Google Scholar
• Herman, M. P. et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J. Clin. Invest. 107, 1117–1126 (2001).
  CAS PubMed PubMed Central Google Scholar
• Mott, J. D. et al. Post-translational proteolytic processing of procollagen C-terminal proteinase enhancer releases a metalloproteinase inhibitor. J. Biol. Chem. 275, 1384–1390 (2000).
  CAS PubMed Google Scholar
• Petitclerc, E. et al. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J. Biol. Chem. 275, 8051–8061 (2000).
  CAS PubMed Google Scholar
• Stetefeld, J. et al. The laminin-binding domain of agrin is structurally related to N-TIMP-1. Nature Struct. Biol. 8, 705–709 (2001).
  CAS PubMed Google Scholar
• Hua, J. & Muschel, R. J. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 56, 5279–5284 (1996).
  CAS PubMed Google Scholar
• Kondraganti, S. et al. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res. 60, 6851–6855 (2000).
  CAS PubMed Google Scholar
• Nagavarapu, U., Relloma, K. & Herron, G. S. Membrane type 1 matrix metalloproteinase regulates cellular invasiveness and survival in cutaneous epidermal cells. J. Invest. Dermatol. 118, 573–581 (2002).
  CAS PubMed Google Scholar
• Ma, Z., Qin, H. & Benveniste, E. N. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-γ and IFN-β: critical role of STAT-1α. J. Immunol. 167, 5150–5159 (2001).
  CAS PubMed Google Scholar
• Slaton, J. W. et al. Treatment with low-dose interferon-α restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin. Cancer Res. 7, 2840–2853 (2001).
  CAS PubMed Google Scholar
• Mengshol, J. A., Mix, K. S. & Brinckerhoff, C. E. Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark? Arthritis Rheum. 46, 13–20 (2002).
  CAS PubMed Google Scholar
• Lal, A. et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 62, 3335–3339 (2002).
  CAS PubMed Google Scholar
• Muraoka, R. S. et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109, 1551–1559 (2002).
  CAS PubMed PubMed Central Google Scholar
• McGaha, T. L., Phelps, R. G., Spiera, H. & Bona, C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-β-mediated Smad3 activation in fibroblasts. J. Invest. Dermatol. 118, 461–470 (2002).
  CAS PubMed Google Scholar
• Shin, M., Yan, C. & Boyd, D. An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim. Biophys. Acta 1589, 311–316 (2002).
  CAS PubMed Google Scholar
• Futamura, M. et al. Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibit Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells. Oncogene 20, 6724–6730 (2001).
  CAS PubMed Google Scholar
• Zhang, Y. et al. Hyaluronan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a human lung carcinoma cell line QG90. Cancer Res. 62, 3962–3965 (2002).
  CAS PubMed Google Scholar
• Karin, M. & Chang, L. AP-1-glucocorticoid receptor crosstalk taken to a higher level. J. Endocrinol. 169, 447–451 (2001).
  CAS PubMed Google Scholar
• Sato, T. et al. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res. 62, 1025–1029 (2002).
  CAS PubMed Google Scholar
• Mohan, R. et al. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J. Biol. Chem. 275, 10405–10412 (2000).
  CAS PubMed Google Scholar
• Adams, J. et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615–2622 (1999).
  CAS PubMed Google Scholar
• Mix, K. S. et al. A synthetic triterpenoid selectively inhibits the induction of matrix metalloproteinases 1 and 13 by inflammatory cytokines. Arthritis Rheum. 44, 1096–1104 (2001).
  CAS PubMed Google Scholar
• Pan, M. R., Chuang, L. Y. & Hung, W. C. Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett. 508, 365–368 (2001).
  CAS PubMed Google Scholar
• Ala-aho, R., Grenman, R., Seth, P. & Kahari, V. M. Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells. Oncogene 21, 1187–1195 (2002).
  CAS PubMed Google Scholar
• Koul, D. et al. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20, 6669–6678 (2001).
  CAS PubMed Google Scholar
• Fenrick, R. et al. TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. Mol. Cell. Biol. 20, 5828–5839 (2000).
  CAS PubMed PubMed Central Google Scholar
• Lund, L. R. et al. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J. 18, 4645–4656 (1999).
  CAS PubMed PubMed Central Google Scholar
• Galvez, B. G., Matias-Roman, S., Albar, J. P., Sanchez-Madrid, F. & Arroyo, A. G. Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J. Biol. Chem. 276, 37491–37500 (2001).
  CAS PubMed Google Scholar
• van Lent, P. L., Holthuysen, A. E., Sloetjes, A., Lubberts, E. & van den Berg, W. B. Local overexpression of adeno-viral IL-4 protects cartilage from metallo proteinase-induced destruction during immune complex-mediated arthritis by preventing activation of pro-MMPs. Osteoarthr. Cartilage 10, 234–243 (2002).
  CAS Google Scholar
• Annabi, B. et al. Green tea polyphenol (–)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells. Biochim. Biophys. Acta 1542, 209–220 (2002).
  CAS PubMed Google Scholar
• Bassi, D. E. et al. Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc. Natl Acad. Sci. USA 98, 10326–10331 (2001).
  CAS PubMed PubMed Central Google Scholar
• Khatib, A. M. et al. Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am. J. Pathol. 160, 1921–1935 (2002).
  CAS PubMed PubMed Central Google Scholar
• Maquoi, E. et al. Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Lett. 424, 262–266 (1998).
  CAS PubMed Google Scholar
• Basset, P. et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 348, 699–704 (1990).
  CAS PubMed Google Scholar
• Bein, K. & Simons, M. Thrombospondin type 1 repeats interact with matrix metalloproteinase 2. Regulation of metalloproteinase activity. J. Biol. Chem. 275, 32167–32173 (2000).
  CAS PubMed Google Scholar
• Rodriguez-Manzaneque, J. C. et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl Acad. Sci. USA 98, 12485–12490 (2001).
  CAS PubMed PubMed Central Google Scholar
• Yang, Z., Strickland, D. K. & Bornstein, P. Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J. Biol. Chem. 276, 8403–8408 (2001).
  CAS PubMed Google Scholar
• Kim, Y. M. et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res. 60, 5410–5413 (2000).
  CAS PubMed Google Scholar
• Nakada, M. et al. Suppression of membrane-type 1 matrix metalloproteinase (MMP)-mediated MMP-2 activation and tumor invasion by testican 3 and its splicing variant gene product, N-tes. Cancer Res. 61, 8896–8902 (2001).
  CAS PubMed Google Scholar
• Bigg, H. F. et al. Tissue inhibitor of metalloproteinases-4 (TIMP-4) inhibits, but does not support, the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res. 61, 3610–3618 (2001).
  CAS PubMed Google Scholar
• Butler, G. S. et al. The TIMP2 membrane type 1 metalloproteinase 'receptor' regulates the concentration and efficient activation of progelatinase A. A kinetic study. J. Biol. Chem. 273, 871–880 (1998).
  CAS PubMed Google Scholar
• Sgadari, C. et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nature Med. 8, 225–232 (2002).Illustrates the feasibility of targeting proMMP activation for cancer therapy. The paper demonstrates that HIV-protease inhibitors are able to block proMMP-2 activation, and this effect is associated with the regression of sarcomas in HIV patients.
  CAS PubMed Google Scholar
• Andre, P. et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl Acad. Sci. USA 95, 13120–13124 (1998).
  CAS PubMed PubMed Central Google Scholar
• Liang, J. S. et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nature Med. 7, 1327–1331 (2001).
  CAS PubMed Google Scholar
• Kruger, A., Fata, J. E. & Khokha, R. Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood 90, 1993–2000 (1997).
  CAS PubMed Google Scholar
• Martin, D. C. et al. Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis. Lab. Invest. 79, 225–234 (1999).
  CAS PubMed Google Scholar
• Brown, P. D. Clinical studies with matrix metalloproteinase inhibitors. APMIS 107, 174–180 (1999).
  CAS PubMed Google Scholar
• Duivenvoorden, W. C. et al. Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Res. 62, 1588–1591 (2002).
  CAS PubMed Google Scholar
• Cianfrocca, M. et al. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J. Clin. Oncol. 20, 153–159 (2002).
  CAS PubMed Google Scholar
• Boissier, S. et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60, 2949–2954 (2000).
  CAS PubMed Google Scholar
• Hidalgo, M. & Eckhardt, S. G. Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl Cancer Inst. 93, 178–193 (2001).
  CAS PubMed Google Scholar
• Bramhall, S. R., Rosemurgy, A., Brown, P. D., Bowry, C. & Buckels, J. A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 19, 3447–3455 (2001).
  CAS PubMed Google Scholar
• Bramhall, S. R. et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and Marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 87, 161–167 (2002).
  CAS PubMed PubMed Central Google Scholar
• Groves, M. D. et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, Marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol 20, 1383–1388 (2002).This work provides support to the hypothesis that MMPIs, in combination with other drugs, might improve the clinical outcome of cancer patients.
  CAS PubMed Google Scholar
• Zucker, S., Cao, J. & Chen, W. T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642–6650 (2000).
  CAS PubMed Google Scholar
• Fingleton, B., Heppner Goss, K. J., Crawford, H. C. & Matrisian, L. M. Matrilysin in early stage intestinal tumorigenesis. APMIS 107, 102–110 (1999).
  CAS PubMed Google Scholar
• Pozzi, A., LeVine, W. F. & Gardner, H. A. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 22, 272–281 (2002).
  Google Scholar
• Kruger, A. et al. Hydroxamate-type matrix metalloproteinase inhibitor promotes liver metastasis. Cancer Res. 61, 1272–1275 (2001).
  CAS PubMed Google Scholar
• Maquoi, E. et al. Stimulation of matrix metalloproteinase-9 expression in human fibrosarcoma cells by synthetic matrix metalloproteinase inhibitors. Exp. Cell Res. 275, 110–121 (2002).
  CAS PubMed Google Scholar
• Toth, M. et al. Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (membrane type 1)-MMP-dependent activation of pro-MMP-2. J. Biol. Chem. 275, 41415–41423 (2000).
  CAS PubMed Google Scholar
• Vazquez, F. et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J. Biol. Chem. 274, 23349–23357 (1999).
  CAS PubMed Google Scholar
• Gomis-Ruth, F. X. et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 389, 77–81 (1997).
  CAS PubMed Google Scholar
• Bode, W. et al. Structural properties of matrix metalloproteinases. Cell Mol. Life Sci. 55, 639–652 (1999).
  CAS PubMed Google Scholar
• Turk, B. E, Huang, L. L., Piro, E. T. & Cantley, L. C. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nature Biotechnol. 19, 661–667 (2001).
  CAS Google Scholar
• Koivunen, E. et al. Tumor targeting with a selective gelatinase inhibitor. Nature Biotechnol. 17, 768–774 (1999).
  CAS Google Scholar
• Bernardo, M. M., Brown, S., Li, Z. H., Fridman, R. & Mobashery, S. Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J. Biol. Chem. 277, 11201–11207 (2002).
  CAS PubMed Google Scholar
• Garbisa, S. et al. Tumor gelatinases and invasion inhibited by the green tea flavonol epigallocatechin-3-gallate. Cancer 91, 822–832 (2001).
  CAS PubMed Google Scholar
• Falardeau, P., Champagne, P., Poyet, P., Hariton, C. & Dupont, E. Neovastat, a naturally-occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin. Oncol. 28, 620–625 (2001).
  CAS PubMed Google Scholar
• Baker, A. H., George, S. J., Zaltsman, A. B., Murphy, G. & Newby, A. C. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br. J. Cancer. 79, 1347–1355 (1999).
  CAS PubMed PubMed Central Google Scholar
• Bello, L. et al. Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res. 61, 8730–8736 (2001).Analysis of possibilities of disrupting non-catalytic activities of MMPs.
  CAS PubMed Google Scholar
• Du, L. et al. cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. Genomics 36, 22–28 (1996).
  CAS PubMed Google Scholar
• Pfeifer, A., Kessler, T., Silletti, S., Cheresh, D. A. & Verma, I. M. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc. Natl Acad. Sci. USA 97, 12227–12232 (2000).
  CAS PubMed PubMed Central Google Scholar
• Silletti, S., Kessler, T., Goldberg, J., Boger, D. L. & Cheresh, D. A. Disruption of matrix metalloproteinase 2 binding to integrin αvβ3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl Acad. Sci. USA 98, 119–124 (2001).
  CAS PubMed Google Scholar
• Tam, E., Wu, Y. I., Butler, G. S., Stack, S. M. & Overall, C. M. Collagen binding properties of the MT1-MMP hemopexin C domain: the ectodomain of the 44-kDa autocatalytic fragment of MT1–MMP inhibits cell invasion by disrupting native type I collagen cleavage. J. Biol. Chem. 25 Jul 2002 [epub ahead of print].
• Peng, K. W., Vile, R., Cosset, F. L. & Russell, S. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther. 6, 1552–1557 (1999).Together with references 142 and 143 , this paper is an example of novel strategies for cancer therapy that is based on exploiting MMP function.
  CAS PubMed Google Scholar
• Liu, S., Netzel-Arnett, S., Birkedal-Hansen, H. & Leppla, S. H. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res. 60, 6061–6067 (2000).
  CAS PubMed Google Scholar
• Hayashi, M., Tomita, M. & Yoshizato, K. Interleukin-2-collagen chimeric protein which liberates interleukin-2 upon collagenolysis. Protein Eng. 15, 429–436 (2002).
  CAS PubMed Google Scholar
• Lippman, S. M. & Matrisian, L. M. Protease inhibitors in oral carcinogenesis and chemoprevention. Clin. Cancer Res. 6, 4599–4603 (2000).
  CAS PubMed Google Scholar
• Balbin, M. et al. Identification and enzymatic characterization of two diverging murine counterparts of human interstitial collagenase (MMP-1) expressed at sites of embryo implantation. J. Biol. Chem. 276, 10253–10262 (2001).
  CAS PubMed Google Scholar
• Weissleder, R. Scaling down imaging: molecular mapping of cancer in mice. Nature Rev. Cancer 2, 11–18 (2002).Excellent discussion of potential solutions to the problem of assessment of in vivo inhibition of MMPs.
  CAS Google Scholar
• Schatzkin, A. & Gail, M. The promise and peril of surrogate end points in cancer research. Nature Rev. Cancer 2, 19–27 (2002).
  CAS Google Scholar
• Gross, J. & Lapiere C. M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl Acad. Sci. USA 48, 1014–1022 (1962).The first demonstration of an animal collagenase that is active at neutral pH, normal temperature and isotonicity: the starting point of studies on MMPs.
  CAS PubMed PubMed Central Google Scholar
• Hirohata, S. et al. Punctin, a novel ADAMTS-like molecule, ADAMTSL-1, in extracellular matrix. J. Biol. Chem. 277, 12182–12189 (2002).
  CAS PubMed Google Scholar
• Levitt, N. C. et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin. Cancer Res. 7, 1912–1922 (2001).
  CAS PubMed Google Scholar